Status:

COMPLETED

StrataGraft™ Skin Tissue (Human Donor Skin) In The Surgical Management Of Complex Skin Defects

Lead Sponsor:

Stratatech, a Mallinckrodt Company

Collaborating Sponsors:

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Conditions:

Third Degree Burn

Burns

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

This pilot Phase I/II clinical study will be conducted at up to three clinical sites. This is an open-label, randomized, comparative study with a maximum of fifteen (15) patients, each with skin defe...

Detailed Description

Stratatech has completed a phase I/IIa clinical study to assess the safety and efficacy of escalating amounts of StrataGraft skin tissue in patients with complex skin defects requiring sequential debr...

Eligibility Criteria

Inclusion

  • Patients aged greater than 18 yrs.
  • Patients with complex skin defects requiring sequential debridement under anesthesia with temporary biological dressing (allogeneic grafting) prior to autografting
  • Full-thickness skin defects
  • Informed consent

Exclusion

  • Prisoners
  • Pregnant (positive urinary pregnancy in women of child-bearing potential at Visit#1) or lactating females
  • Immunosuppressive therapy
  • Infection with Human Immunodeficiency Virus
  • Venous stasis ulcers of the lower leg
  • Diabetic foot ulcers
  • Donor site wounds
  • Wounds of less than 5% body surface area
  • Wounds of the hands, face, and feet (although such wound surface areas can be counted toward total injured BSA)
  • Prior entry into this study
  • Expected survival of less than 3 months
  • Concomitant processes sustained contemporaneously with the dermal injury (e.g., inhalational injury requiring ventilation, electrical injury with cardiac damage or arrhythmia, sepsis, other serious or unstabilized organ damage from trauma, etc.)
  • Use of an investigational agent within 30 days
  • Active malignancy
  • Clinical evidence of malnutrition
  • Clinically significant renal, hepatic, cardiac, pulmonary, or neurological impairments

Key Trial Info

Start Date :

July 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2008

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT00618839

Start Date

July 1 2006

End Date

April 1 2008

Last Update

October 16 2019

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Arizona Burn & Trauma Center

Phoenix, Arizona, United States, 85008

2

University of Wisconsin-Hospital and Clinics

Madison, Wisconsin, United States, 53792